• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·4911.TWO
Share

G&E Herbal Biotechnology Co., Ltd. Stocks

NT$ 35.7Last Updated 24.07.2026

Issuer Rating

3/7
Performance

Average

Risk

Considerable

Recommendation

Sell

Market Cap

NT$ 68.62M

NT$ 35.7
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

G&E Herbal Biotechnology Co., Ltd. operates as a biopharmaceutical enterprise, concentrating on the innovation and commercialization of advanced botanical extraction technologies and the products derived from them. Its diverse portfolio features a range of botanical anti-aging cosmetic items, including facial foam cleansers, cleansing essences, toners, lightening lotions, essential oils, and moisturizing serums and creams, along with specialized products like the SR-100 botanical essence and bromelain illuminating cleansing mousse. The company also manufactures capsules designed as hepato-protective agents. In the realm of wellness, G&E offers a selection of botanical healthcare products such as ArthrEnergy, Jujubes Polysaccharide, Diabecut, HepatoClean, Astragali Radix, Goji, Prosta, and SR-100 capsules, as well as various products catering to adults. Looking to its future developments, the company is actively pursuing new treatments, including Solarise injection for gynecologic, head, and neck cancers; Apocin capsules intended for non-small cell lung cancer; and SR-T100 Gel, which targets common and genital warts. Beyond its own product lines, G&E Herbal Biotechnology is involved in creating manufacturing technologies for a wide array of dietary supplements and provides expert technical advisory services to other biotechnology organizations. The company was founded in 2002 and is headquartered in Tainan City, Taiwan.

Company Valuation

Overvalued
2/7

Based on key historical and expected multiples, the stock is overvalued relative to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITDA, over

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

25.07.2026 08:00

AI Spending Threatens the Creditworthiness of Amazon, Meta, and Alphabet — Moody’s

25.07.2026 06:24

In July, four out of five of the short seller's bets from *The Short Game* paid off. Which ones?

25.07.2026 05:59

Nvidia and Palantir Urged the U.S. Not to Restrict "Open" AI Models Following China's Breakthrough

25.07.2026 05:03

SpaceX has successfully tested the Starship rocket for the first time since its IPO

25.07.2026 04:30

Paramount has put its merger with Warner Bros. on hold for nearly a year

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026